Få 200 $ for at oprette en Interactive Brokers-konto med vores link: Opret IBKR-konto. Læs vores analyse af Interactive Brokers

Ticker
CRL

Price
224.03
Stock movement up
+2.61 (1.64%)
Company name
Charles River Laboratories
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Markedsværdi
7.94B
Ent værdi
11.80B
Pris/omsætning
1.97
Pris/bog
2.30
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
14.73
PEG
-
EPS-vekst
-47.65%
1 års afkast (CAGR)
4.77%
3 års afkast (CAGR)
-14.47%
5 års afkast (CAGR)
-10.22%
10 års afkast (CAGR)
8.70%
Senest opdateret: 2026-02-13

UDBYTTE

CRL betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF10.60
Pris til FCF14.61
Pris til EBITDA15.38
EV i forhold til EBITDA22.84

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning1.97
Pris til egenkapital2.30
EV i forhold til salg2.93

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier49.22M
EPS (TTM)-1.69
FCF pr. aktie (TTM)11.00

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)4.02B
Bruttofortjeneste (TTM)1.30B
Driftsindkomst (TTM)140.91M
Nettoindkomst (TTM)-83.48M
EPS (TTM)-1.69
EPS (1 år frem)10.95

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)32.25%
Driftsmargin (TTM)3.50%
Fortjenstmargin (TTM)-2.07%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter207.67M
Nettotilgodehavender734.48M
Omsætningsaktiver i alt1.53B
Goodwill2.92B
Immaterielle aktiver571.09M
Ejendomme, anlæg og udstyr3.46B
Sum aktiver7.51B
Kreditor169.62M
Kortfristet/nuværende langsigtet gæld2.63B
Summen af kortfristede forpligtelser1.12B
Sum gæld4.06B
Aktionærernes egenkapital3.45B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)749.49M
Investeringsudgifter (TTM)205.82M
Fri pengestrøm (TTM)543.67M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-2.42%
Afkast af aktiver-1.11%
Afkast af investeret kapital-2.42%
Kontant afkast af investeret kapital15.74%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning160.44
Daglig høj163.15
Daglig lav156.58
Daglig volumen932K
Højeste gennem alle tider458.30
1 års analytiker estimat215.73
Beta1.62
EPS (TTM)-1.69
Udbytte pr. aktie0.00
Ex-div dato-
Næste dato for resultatpræsentation18 Feb 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
CRLS&P500
Nuværende prisfald fra top notering-51.12%-0.89%
Højeste prisfald-78.23%-56.47%
Højeste efterår dato11 Apr 20259 Mar 2009
Gennemsnitlig fald fra toppen-25.28%-10.86%
Gennemsnitlig tid til nyt højdepunkt22 days12 days
Maks. tid til nyt højdepunkt1611 days1805 days

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
CRL (Charles River Laboratories) company logo
Markedsværdi
7.94B
Markedsværdi kategori
Mid-cap
Beskrivelse
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington, Mas
Personale
18700
Investor relationer
-
SEC-indsendelser
Adm. direktør
James C. Foster
Land
USA
By
Wilmington
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...